Novelties in Maintenance Therapy for Ovarian Cancer

Speaker: Isabelle Ray Coquard

I. Ray-Coquard elaborates the results from a randomised, phase III study of maintenance therapy with a PARP inhibitor niraparib in platinum-sensitive recurrent ovarian cancer. The trial met primary endpoint with niraparib prolonging progression-free survival compared to placebo, the finding seen in germline BRCA mutation group and in a non-mutation cohort with homologous recombination DNA repair deficiencies.

Discussion Points

  1. Key study findings
  2. Rationale for the study
  3. Practice perspective
  4. Future steps

Abstract LBA3_PR: A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)